Passer au contenu principal

Richard LeBlanc

Richard LeBlanc

Clinical Associate Professor

Affiliation

Université de Montréal

Research Axes

Clinical research

Contact information

Phone: 514 252-3400 , poste 3404

rleblanc.hmr@ssss.gouv.qc.ca

A hematologist and medical oncologist, Dr. Richard LeBlanc is also the medical chief of the Clinical Immunology Laboratory and head of the Multiple Myeloma Clinical Research Unit team. Dr. LeBlanc is a Clinical Associate Professor in the Department of Medicine at Université de Montréal and is the Myeloma Canada Chair on Multiple Myeloma.

Research Unit

Multiple myeloma is an incurable hematologic cancer involving a type of white blood cell called plasma cells. Current therapies only have a palliative impact on the disease.

Since 2008, the Multiple Myeloma Research Unit team has participated in over 30 international and national clinical trials on various multiple myeloma therapies. Many of these studies have led to the approval of new drugs that are now available as standard treatment to improve care for multiple myeloma patients.

New therapeutic modalities being developed hold great promise for improving survival rates and quality of life for patients with this disease. Immunotherapy even has the potential to be a cure.

In collaboration with the Hematopoietic Stem Cell Transplantation research team, the Multiple Myeloma research team has developed original studies on allogeneic transplantation and the treatment of multiple myeloma associated with a potential cure.

  • LeBlanc R, Claveau JS, Ahmad I, Bambace N, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Landais S, Roy DC, Sauvageau G, Roy J. Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only. Clinical Transplantation 2020, accepté
  • Richardson PG, Nagler A, Ben-Yehuda D, Badros A, Hari PN, Hajek R, Spicka I, Kaya H, LeBlanc R, Yoon, SS, Kim K, Martinez-Lopez J, Mittelman M, Shpilberg O, Tothova E, Blake P, Colson K, Laubach JP, Ghobrial IM, Leiba M, Gatt ME, Sportelli P, Chen M and Anderson KC. Randomised, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. eJHaem 2020, accepté
  • Bergstrom DJ, Kotb R, Louzada ML, Sutherland HJ, Tavoularis S, Venner CP (LeBlanc R as a reviewer). Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders. Myeloma Canada Research Network Consensus Guideline Consortium Recommendations. Clin Lymphoma Myeloma and Leuk 2020, 20: e352-e367
  • Royal V, Leung N, Troyanov S, Nasr S, Écotière L, LeBlanc R, Adam B, Alexander MP, Angioi A, Asuntis AM, Barraca A, Bianco P, Cohen C, Drosou ME, Fatima H, Fenoglio R, Gougeon F, Goujon JM, Herrera GA, Knebelmann B, Lepori N, Maletta F, Manso R, Motwani SS, Pani A, Rabant M, Rennke HG, Roccatello D, Rosenblum F, Sanders PW, Sis B, Soto K, Touchard G, Venner CP and Bridoux F. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: A multicenter retrospective study. Blood 2020, 135 : 1833-1846
  • Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group (including LeBlanc R). Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019; 394: 2096-2107
  • LeBlanc R, Song K, White D, Christofides A, Doucette S. Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma. Current Oncol 2019, 26: e581-e594
  • Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 (including LeBlanc R). Investigtors.Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol 2019; 6 : e459-e469
  • Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Boon Ming Lim A, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San Miguel J. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol 2019; 6 : e448-e458
  • Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, McKiver MP, Jou YM, Shelat SG, Robbins M, Rafferty B, San Miguel J. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med 2018, 379 : 1811-1822
  • Claveau JS, LeBlanc R, Ahmad I, Ferreira J, Pistono AA, Bambace N, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Roy J. Cerebral adenovirus endotheliitis presenting as posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation. Bone Marrow Transplant 2017; 52: 1457-1459
  • Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu Z, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T. Updated Outcomes and Impact of Age With
    Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase 3 FIRST Trial. Journal of Clinical Oncology 2016, 34: 3609-3617

  • Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators (including LeBlanc R). Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016; 375: 1319-1331
  • LeBlanc R, Hollmann S, Tay J. Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant. J Popul Ther Clin Pharmacol 2016; 23: e103-113
  • Lonial S, Weiss B, Usmani S, Singhal S, Chari A, Bahlis, N, Belch A, Krishnan A, Vescio R, Mateos MV, Mazumder A, Orlowski RZ, Sutherland H, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees P. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016; 387: 1551-1560
  • Ahmad I, LeBlanc R, Cohen S, Lachance S, Kiss T, Sauvageau G, Roy DC, Busque L, Delisle JS, Bambace N, Bernard L, Sabry W, Roy J. Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation. Bone Marrow Transplant 2016; 51: 529-535
  • Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators (including LeBlanc R). Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016; 17: 27-38
  • Royal V, Quint P, Leblanc M, LeBlanc R, Duncanson GF, Perrizo RL, Fervenza FC, Kurtin P, Sethi S. IgD Heavy Chain Deposition Disease: Detection by Laser Microdissection and Mass Spectrometry. Journal of American Society of Nephrology 2015; 26: 784-790
  • Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team (including LeBlanc R). Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014; 371: 906-17
  • San-Miguel J, Hungria V, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak W, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncology 2014; 15: 1195-1206
  • San-Miguel JF, Richardson PG, Günther A, Sezer O, Siegel D, Bladé J, LeBlanc R, Sutherland H, Sopala M, Mishra KK, Mu S, Bourquelot PM, Mateos MV, Anderson KC. Phase Ib Study Of Panobinostat and Bortezomib In Relapsed or Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology 2013; 31: 3696-3703
  • Reece D, Song K, LeBlanc R, Mezzi K, Olujohungbe A, White D, Zaman F, Belch A. Efficacy and Safety of Busulfan-based conditioning regimens for multiple myeloma. Oncologist 2013; 18: 611-618
  • Holbro A, Ahmad I, Cohen S, Roy J, Lachance S, Chagnon M, LeBlanc R, Bernard L, Busque L, Roy DC, Sauvageau G, Kiss T. Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma. Biology of Blood Marrow Transplantation 2013; 19: 547-551
  • Reece D, Kouroukis T, LeBlanc R, Sebag M, Song K, Ashkenas J. Practical approaches to the use of Lenalidomide in Multiple Myeloma: A Canadian Consensus. Advances in Hematology 2012; 621958
  • Reece D, Leitch HA, Atkins H, Canning LA, Voralia M, LeBlanc R, Belch AR, White D, Kovacs MJ. Treatment of Relapsed and Refractory Myeloma: A Review of the Literature. Leukemia Lymphoma 2008; 49: 1470-1485
  • Plante M, Lau S, Brydon E, Swenerton K, LeBlanc R, Roy M. Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage 1B1 cervical cancer: case report. Gynecologic Oncology 2006; 101: 367-370
  • Altun M, Galardy PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL, Kessler BM. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Research 2005; 65: 7896-901
  • Lin B, Catley L, LeBlanc R, Mitsiades C, Burger R, Tai YT, Podar K, Wartmann M, Chauhan D, Griffin JD, Anderson KC. Patupilone (Epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood 2005; 105: 350-357
  • LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004; 103: 1787-1790
  • Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003; 102: 2615-22
  • Lentzsch S, LeBlanc R, Podar K, Lin B, Stirling, Anderson KC. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003; 17: 41-4
  • LeBlanc R, Catley L, Hideshima T, Lentzsch S, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research 2002; 62: 4996-5000
  • Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, et al. Immunomodulatory derivative of thalidomide CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067
  • Gupta D, Podar K, Tai YT, Lin B, Hideshima T, Akiyama M, LeBlanc R, et al. β-Lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Experimental Hematology 2002; 30: 711-720
  • Chauhan D, Catley L, Sattler M, Li G, Hideshima T, LeBlanc R, Gupta D, Richardson P, Schlossman RL, Podar K, Munshi N, Anderson K. 2-methoxyestradiol (2ME2) acts directly on tumor cells and in the bone marrow microenvironment to overcome drug resistance in multiple myeloma cells. Blood 2002; 100: 2187-2194
  • Lentzsch S, Roger MS, LeBlanc R, Birsner AE, Shah JH, Treston AM, Anderson KC, D’Amato RJ. S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Research 2002; 62: 2300-2305
  • LeBlanc R, Roy J, Demers C, Vu L and Cantin G. A clinical study on the effect of G-CSF on the hemostasis of healthy bone marrow donors. Bone Marrow Transplant 1999; 23: 991-996

Education

  • Residency in internal medicine

    Université Laval

  • Residency in hematology

    Université Laval

  • Basic research fellowship in multiple myeloma/immunology

    Dana-Farber Cancer Institute